Rose BioSolutions, a leading provider of advanced manufacturing capabilities and cellular materials across the cell and gene therapy space, announced the appointment of David Enloe as Chief Executive Officer.
"As one of the pioneers who helped build the cell and gene therapy industry from its earliest days, David has an exceptional ability to anticipate where the field is headed and what clients will need next," said Dave Kreter, Managing Director and Head of Healthcare Investments at GI Partners. "We are pleased to welcome a leader of his caliber to Rose Bio. We believe David will leverage the company's talented team, differentiated capabilities, and significant market opportunities to accelerate growth and strengthen Rose Bio's position as a leading end-to-end partner across the development and manufacturing lifecycle. We look forward to supporting David and the entire Rose Bio team as they build on the company's strong foundation to deliver the high-quality services clients rely on not only today, but as their programs evolve."
"I am excited to join Rose Bio at a pivotal moment for both the company as a newly established standalone platform and the broader cell and gene therapy industry," said Mr. Enloe. "I have spent much of my career building businesses around emerging science and helping clients advance cutting-edge therapies for patients who need them most. Rose Bio's broad portfolio of cellular starting materials, deep technical expertise and talented team, established infrastructure, and entrepreneurial culture position us to meet our clients' evolving needs and become the integrated partner this industry needs for its next chapter of innovation and patient care."